Rep. Marjorie Taylor Greene Purchases Shares of Merck & Co., Inc. (NYSE:MRK)

Key Points

• Representative Marjorie Taylor Greene disclosed purchasing between $1,001 and $15,000 in shares of Merck & Co., Inc. on August 28th, as per a filing made on August 29th.
• Merck announced a quarterly dividend of $0.81 to be paid on October 7th, resulting in an annualized dividend yield of 3.9%.
• Merck's recent earnings report showed $2.13 earnings per share, exceeding analysts' expectations, with a focus on their 9.01 EPS forecast for the current fiscal year.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. NYSE: MRK. In a filing disclosed on August 29th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on August 28th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Southern NYSE: SO on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Morgan Stanley NYSE: MS on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Novo Nordisk A/S NYSE: NVO on 8/28/2025.
• Purchased $15,001 - $50,000 in shares of Exelon NASDAQ: EXC on 8/28/2025.
• Purchased $15,001 - $50,000 in shares of Ryman Hospitality Properties NYSE: RHP on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 8/28/2025.

Merck & Co., Inc. Stock Down 1.5%

Merck & Co., Inc. stock traded down $1.27 during trading hours on Wednesday, hitting $84.21. The company had a trading volume of 12,175,891 shares, compared to its average volume of 10,265,783. The firm's fifty day moving average is $82.32 and its 200-day moving average is $83.00. The firm has a market capitalization of $210.33 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 0.89 and a beta of 0.37. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $120.30. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The firm had revenue of $15.81 billion during the quarter, compared to analysts' expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be issued a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.8%. Merck & Co., Inc.'s dividend payout ratio is currently 49.92%.

Wall Street Analyst Weigh In

MRK has been the subject of several recent research reports. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Cantor Fitzgerald cut Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Citigroup reissued a "neutral" rating and set a $84.00 price target (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $107.44.

Institutional Trading of Merck & Co., Inc.

Several hedge funds and other institutional investors have recently modified their holdings of MRK. Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. in the second quarter worth approximately $31,000. Total Investment Management Inc. bought a new position in Merck & Co., Inc. in the 2nd quarter worth about $156,000. Barnes Wealth Management Group Inc grew its stake in Merck & Co., Inc. by 11.1% during the 2nd quarter. Barnes Wealth Management Group Inc now owns 2,870 shares of the company's stock worth $227,000 after buying an additional 286 shares during the last quarter. Orion Porfolio Solutions LLC grew its stake in shares of Merck & Co., Inc. by 0.7% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 126,815 shares of the company's stock worth $10,039,000 after purchasing an additional 876 shares during the period. Finally, Thrivent Financial for Lutherans raised its holdings in Merck & Co., Inc. by 51.4% in the 2nd quarter. Thrivent Financial for Lutherans now owns 2,221,342 shares of the company's stock valued at $175,841,000 after acquiring an additional 753,681 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.